Company news

Evofem Biosciences, Inc. news in 2024

Evofem Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

November 13, 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

November 7, 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

November 5, 2024

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

November 5, 2024

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11: 30 AM Eastern Time

October 29, 2024

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

October 28, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

October 27, 2024

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11: 30 AM Eastern Time

October 20, 2024

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

October 7, 2024

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

October 2, 2024

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

September 23, 2024

Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

September 19, 2024

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

September 8, 2024

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

August 28, 2024

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

August 19, 2024

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

August 13, 2024

OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing

August 1, 2024

Watch the Evofem Biosciences, Inc. Presentation at the 8/1/2024 OTCQB Venture Virtual Investor Conference

August 1, 2024

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

July 24, 2024

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

July 22, 2024

Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

July 16, 2024

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

June 26, 2024

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

June 10, 2024

Evofem Biosciences Announces Financial Results for the First Quarter of 2024

May 14, 2024

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

April 17, 2024

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

March 26, 2024

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

March 19, 2024

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

March 6, 2024

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

January 31, 2024

Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game

January 7, 2024

Decks in 2024